Cost consequences of the 340B drug discount program

JAMA. 2013 May 15;309(19):1995-6. doi: 10.1001/jama.2013.4156.
No abstract available

MeSH terms

  • Antineoplastic Agents / economics
  • Cancer Care Facilities / economics
  • Commerce
  • Cost Savings*
  • Cost Sharing
  • Drug Costs*
  • Drug Industry / economics*
  • Government Programs*
  • Hospitals, Community / economics
  • Insurance, Health
  • Medicaid
  • Patient Protection and Affordable Care Act
  • Practice Patterns, Physicians'
  • United States

Substances

  • Antineoplastic Agents